A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients With B-Cell Non-Hodgkin Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2016
At a glance
- Drugs DI Leu16 IL2 (Primary) ; Rituximab (Primary)
- Indications B cell lymphoma
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov report.
- 10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History